Hims & Hers Health (NYSE: HIMS) is deepening its push into prescription weight management by adding new GLP-1 treatment options to its direct-to-consumer telehealth platform.
The company has entered into a formal partnership with Novo Nordisk, giving patients on its platform access to branded medications including Wegovy and Ozempic.
Both drugs carry strong name recognition among patients and clinicians, making the Novo Nordisk agreement a strategically significant move for the company’s weight-loss business.
Alongside the Novo Nordisk deal, Hims & Hers Health announced the acquisition of Eucalyptus, a move that extends its operational footprint well beyond the United States.
The Eucalyptus deal signals a meaningful shift in the company’s international ambitions, adding scale and reach to a business that was originally built around a narrower set of telehealth categories.
Together, the GLP-1 expansion, the Novo Nordisk partnership, and the Eucalyptus acquisition represent what analysts and investors are increasingly viewing as a new strategic phase for the company.
The stock has responded sharply to the announcements, rising 41.2% over the last 30 days as investor enthusiasm around GLP-1 expansion has built momentum.
However, at a recent price of $33.54, shares are trading approximately 22.8% above the analyst consensus price target of $27.32, raising questions about near-term valuation.
One assessment places the stock at roughly 769.9% above its estimated fair value, highlighting the degree to which current pricing reflects growth expectations rather than present fundamentals.
Execution risk remains a central concern for investors, particularly around how GLP-1 treatments will affect the company’s revenue mix and overall margin profile going forward.
Regulatory exposure tied to GLP-1 drug access and the complexities of integrating an international business through the Eucalyptus acquisition add further layers of uncertainty.
Whether the company can convert its expanded telehealth and weight-loss platform into durable financial results will likely determine if the current premium valuation can be sustained over time.
